Published in Proc Natl Acad Sci U S A on September 18, 2001
Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol (2002) 5.75
Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol (2008) 2.97
APRIL modulates B and T cell immunity. J Clin Invest (2002) 2.07
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood (2009) 1.95
SerpinB1 protects the mature neutrophil reserve in the bone marrow. J Leukoc Biol (2011) 1.60
Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol (2006) 1.43
The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med (2003) 1.23
Transplantation survival is maintained by granzyme B+ regulatory cells and adaptive regulatory T cells. J Immunol (2008) 1.14
Tumor evasion from T cell surveillance. J Biomed Biotechnol (2011) 1.01
Rapid reuptake of granzyme B leads to emperitosis: an apoptotic cell-in-cell death of immune killer cells inside tumor cells. Cell Death Dis (2013) 1.01
The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin Dev Immunol (2011) 0.99
Multipotent adult germ-line stem cells, like other pluripotent stem cells, can be killed by cytotoxic T lymphocytes despite low expression of major histocompatibility complex class I molecules. Biol Direct (2009) 0.98
Visualizing CTL/melanoma cell interactions: multiple hits must be delivered for tumour cell annihilation. J Cell Mol Med (2008) 0.97
Effects of histocompatibility and host immune responses on the tumorigenicity of pluripotent stem cells. Semin Immunopathol (2011) 0.94
Mesenchymal stem cells express serine protease inhibitor to evade the host immune response. Blood (2010) 0.93
Expression of high levels of human proteinase inhibitor 9 blocks both perforin/granzyme and Fas/Fas ligand-mediated cytotoxicity. Cell Immunol (2007) 0.91
DNA vaccines, electroporation and their applications in cancer treatment. Hum Vaccin Immunother (2015) 0.89
Crosstalk between CTC, Immune System and Hypoxic Tumor Microenvironment. Cancer Microenviron (2014) 0.87
Modulation of the granzyme B inhibitor proteinase inhibitor 9 (PI-9) by activation of lymphocytes and monocytes in vitro and by Epstein-Barr virus and bacterial infection. Clin Exp Immunol (2006) 0.87
The role of serpinb9/serine protease inhibitor 6 in preventing granzyme B-dependent hepatotoxicity. Hepatology (2007) 0.87
A novel domain in adenovirus L4-100K is required for stable binding and efficient inhibition of human granzyme B: possible interaction with a species-specific exosite. Mol Cell Biol (2003) 0.86
A sense of tumour for the immune system. Immunology (2002) 0.86
Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization. Cancer Genet Cytogenet (2006) 0.85
SerpinB1 regulates homeostatic expansion of IL-17+ γδ and CD4+ Th17 cells. J Leukoc Biol (2013) 0.83
Immunotherapy in acute leukemia. Semin Hematol (2009) 0.82
Intrahepatic lymphocyte expression of dipeptidyl peptidase I-processed granzyme B and perforin induces hepatocyte expression of serine proteinase inhibitor 6 (Serpinb9/SPI-6). J Immunol (2007) 0.82
IFN-γ Rα is a key determinant of CD8+ T cell-mediated tumor elimination or tumor escape and relapse in FVB mouse. PLoS One (2013) 0.82
Low concentrations of the soy phytoestrogen genistein induce proteinase inhibitor 9 and block killing of breast cancer cells by immune cells. Endocrinology (2008) 0.82
Granzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity. J Immunol (2015) 0.82
Genetically engineered human islets protected from CD8-mediated autoimmune destruction in vivo. Mol Ther (2013) 0.81
Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy. J Clin Invest (2003) 0.81
From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors. Clin Dev Immunol (2011) 0.80
Genetic variants of human granzyme B predict transplant outcomes after HLA matched unrelated bone marrow transplantation for myeloid malignancies. PLoS One (2011) 0.80
MC32 tumor cells acquire Ag-specific CTL resistance through the loss of CEA in a colon cancer model. Hum Vaccin Immunother (2015) 0.80
Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications. Clin Dev Immunol (2012) 0.80
How to cross immunogenetic hurdles to human embryonic stem cell transplantation. Semin Immunopathol (2011) 0.79
Granzyme M targets topoisomerase II alpha to trigger cell cycle arrest and caspase-dependent apoptosis. Cell Death Differ (2013) 0.79
A functional genomics screen identifies PCAF and ADA3 as regulators of human granzyme B-mediated apoptosis and Bid cleavage. Cell Death Differ (2014) 0.78
CD8 engineered cytotoxic T cells reprogram melanoma tumor environment. Oncoimmunology (2015) 0.78
Induced Pluripotent Stem Cell as a New Source for Cancer Immunotherapy. Genet Res Int (2016) 0.76
Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110. PLoS One (2015) 0.76
Inhibition of Granzyme B by PI-9 protects prostate cancer cells from apoptosis. Prostate (2011) 0.76
A Novel Serpin Regulatory Mechanism: SerpinB9 IS REVERSIBLY INHIBITED BY VICINAL DISULFIDE BOND FORMATION IN THE REACTIVE CENTER LOOP. J Biol Chem (2015) 0.75
Overcoming tumor immune evasion with an unique arbovirus. J Transl Med (2015) 0.75
Digital analysis and epigenetic regulation of the signature of rejection in colorectal cancer. Oncoimmunology (2017) 0.75
Pediatric Primitive Neuroectodermal Tumors of the Central Nervous System Differentially Express Granzyme Inhibitors. PLoS One (2016) 0.75
Systems-level effects of ectopic galectin-7 reconstitution in cervical cancer and its microenvironment. BMC Cancer (2016) 0.75
Granzyme M: behind enemy lines. Cell Death Differ (2014) 0.75
NLRC5/CITA: A Key Player in Cancer Immune Surveillance. Trends Cancer (2017) 0.75
Inhibition of death receptor signals by cellular FLIP. Nature (1997) 9.58
Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science (1994) 7.34
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 6.73
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res (1996) 6.03
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature (1994) 5.58
Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med (2000) 5.04
Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell (1994) 4.26
The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods (1991) 3.33
Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med (2000) 3.04
Decreased tumor surveillance in perforin-deficient mice. J Exp Med (1996) 3.00
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (1998) 2.98
The CTL's kiss of death. Cell (1995) 2.80
Inhibition of fas death signals by FLIPs. Curr Opin Immunol (1998) 2.67
Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol (1996) 2.58
Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res (1975) 2.54
Apoptotic DNA fragmentation. Exp Cell Res (2000) 2.52
Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell (1989) 2.20
Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell (2000) 1.98
The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med (1999) 1.98
New paradigm for lymphocyte granule-mediated cytotoxicity. Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis. J Biol Chem (1996) 1.94
Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med (2000) 1.89
Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med (1999) 1.76
A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem (1996) 1.75
Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. EMBO J (1999) 1.73
Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members bid and Bax. J Exp Med (2000) 1.73
Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res (1992) 1.65
Natural killer and lymphokine-activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells. Proc Natl Acad Sci U S A (1995) 1.59
Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol Cell Biol (1998) 1.59
Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization. J Exp Med (1997) 1.54
DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. Immunity (2000) 1.52
FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol (1998) 1.49
A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med (1997) 1.47
A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med (1995) 1.44
Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by oncogenic Ras. Cancer Res (1998) 1.28
A new family of 10 murine ovalbumin serpins includes two homologs of proteinase inhibitor 8 and two homologs of the granzyme B inhibitor (proteinase inhibitor 9). J Biol Chem (1997) 1.23
The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites. J Immunol (2001) 1.19
A cell line from an induced carcinoma of mouse rectum. J Pathol (1978) 1.16
Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res (1996) 1.15
The death receptors. Results Probl Cell Differ (1999) 1.09
A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. J Exp Med (1993) 1.09
Dendritic cell elimination as an assay of cytotoxic T lymphocyte activity in vivo. J Immunol Methods (2000) 1.04
Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo. Curr Opin Immunol (2000) 1.02
Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376. Cancer Res (1999) 0.96
Granzyme A and B-deficient killer lymphocytes are defective in eliciting DNA fragmentation but retain potent in vivo anti-tumor capacity. Eur J Immunol (2001) 0.88
Escape mechanisms in tumor immunity: a year 2000 update. Crit Rev Oncog (2000) 0.82
T-cell recognition of melanoma antigens and its therapeutic applications. Int J Clin Lab Res (1997) 0.81
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 12.70
B lymphocytes secrete antigen-presenting vesicles. J Exp Med (1996) 11.53
Inhibition of death receptor signals by cellular FLIP. Nature (1997) 9.58
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature (1994) 5.58
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37
A T-cell receptor gamma/CD3 complex found on cloned functional lymphocytes. Nature (1987) 3.81
Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol (1993) 3.73
Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med (1998) 3.72
Pretransplantation blood transfusion revisited. N Engl J Med (1991) 3.72
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med (1995) 3.67
Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell (1990) 3.44
Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci U S A (1991) 3.15
The building blocks of planets within the 'terrestrial' region of protoplanetary disks. Nature (2004) 3.13
The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol (2000) 3.12
Decreased tumor surveillance in perforin-deficient mice. J Exp Med (1996) 3.00
Tumorigenicity of cells transformed by adenovirus type 12 by evasion of T-cell immunity. Nature (1983) 2.96
The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med (1998) 2.94
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol (2001) 2.79
CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med (1999) 2.77
Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med (1998) 2.72
The PINOID protein kinase regulates organ development in Arabidopsis by enhancing polar auxin transport. Development (2001) 2.57
Expression of mouse telomerase catalytic subunit in embryos and adult tissues. Proc Natl Acad Sci U S A (1998) 2.27
CD4 T cells and their role in antitumor immune responses. J Exp Med (1999) 2.27
Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell (1989) 2.20
Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol (1996) 2.14
Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J (1998) 2.13
An Arabidopsis Minute-like phenotype caused by a semi-dominant mutation in a RIBOSOMAL PROTEIN S5 gene. Development (2001) 2.11
Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol (1996) 2.11
The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science (1998) 2.11
Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ (2001) 2.08
Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol (1994) 2.07
Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol (1995) 2.05
Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci U S A (2001) 2.04
Peptide selection by MHC class I molecules. Nature (1991) 2.01
Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L). Proc Natl Acad Sci U S A (1999) 1.99
Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res (2001) 1.92
Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J Immunol (1987) 1.92
Reorganization of multivesicular bodies regulates MHC class II antigen presentation by dendritic cells. J Cell Biol (2001) 1.87
In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol (1993) 1.79
An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein. EMBO J (2002) 1.79
Long-term followup of patients with Sjögren's syndrome. Arthritis Rheum (1996) 1.76
Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med (1999) 1.76
TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). Immunity (1997) 1.74
Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. EMBO J (1999) 1.73
Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci U S A (1996) 1.72
Informed consent for phase I studies: evaluation of quantity and quality of information provided to patients. Ann Oncol (1995) 1.69
Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol (1999) 1.68
The MAL proteolipid is necessary for normal apical transport and accurate sorting of the influenza virus hemagglutinin in Madin-Darby canine kidney cells. J Cell Biol (1999) 1.68
Downregulation of BDNF mRNA and protein in the rat hippocampus by corticosterone. Brain Res (1998) 1.67
Differential effects of the adenovirus E1A oncogene on members of the AP-1 transcription factor family. Mol Cell Biol (1990) 1.66
CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci (1999) 1.66
Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep (2001) 1.66
Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J Exp Med (2001) 1.62
Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J Biol Chem (2001) 1.62
Does training on an anaesthesia simulator lead to improvement in performance? Br J Anaesth (1994) 1.61
Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J Pathol (2007) 1.60
HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol (1998) 1.60
Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells. J Exp Med (1995) 1.60
Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med (2000) 1.56
Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol (1993) 1.55
Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. Cochrane Database Syst Rev (2009) 1.53
Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site. J Immunol (2000) 1.52
Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses. Eur J Immunol (1991) 1.51
Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med (2001) 1.50
FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol (1998) 1.49
Hox gene products modulate the DNA binding activity of Pbx1 and Pbx2. Mech Dev (1995) 1.49
Both Fc receptors and lymphocyte-function-associated antigen 1 on human T gamma lymphocytes are required for antibody-dependent cellular cytotoxicity (killer cell activity). Eur J Immunol (1984) 1.48
Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans. J Immunol (2000) 1.48
The hexapeptide LFPWMR in Hoxb-8 is required for cooperative DNA binding with Pbx1 and Pbx2 proteins. Proc Natl Acad Sci U S A (1995) 1.47
Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses. J Gen Virol (1998) 1.47
Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ (2005) 1.46
Lumbar myelography followed by meningitis. Infect Control Hosp Epidemiol (1992) 1.46
Why do child mortality rates fall? An analysis of the Nicaraguan experience. Am J Public Health (1991) 1.45
Evidence for a protective role of interferon in resistance to murine cytomegalovirus and its control by non-H-2-linked genes. Infect Immun (1982) 1.44
Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer (1999) 1.44
Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. J Immunol (1995) 1.44
Involvement of inhibitory NKRs in the survival of a subset of memory-phenotype CD8+ T cells. Nat Immunol (2001) 1.44
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest (1997) 1.43
Failure or success in the restoration of virus-specific cytotoxic T lymphocyte response defects by dendritic cells. J Immunol (1988) 1.43
Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol (1993) 1.40
Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. J Virol (1999) 1.40